193 related articles for article (PubMed ID: 33772436)
1. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
[TBL] [Abstract][Full Text] [Related]
2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
Xi X; Sun W; Su H; Zhang X; Sun F
Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
[TBL] [Abstract][Full Text] [Related]
6. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
7. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
[TBL] [Abstract][Full Text] [Related]
8. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
Tripathy RK; Pande AH
Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
[TBL] [Abstract][Full Text] [Related]
9. Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling.
Rossotti MA; Henry KA; van Faassen H; Tanha J; Callaghan D; Hussack G; Arbabi-Ghahroudi M; MacKenzie CR
Biochem J; 2019 Jan; 476(1):39-50. PubMed ID: 30455372
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer.
Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT
PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
[TBL] [Abstract][Full Text] [Related]
12. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation.
Li L; Zhu Y; Liu M; Jin D; Zhang L; Cheng J; Liu Y
J Inorg Biochem; 2021 Oct; 223():111553. PubMed ID: 34340059
[TBL] [Abstract][Full Text] [Related]
13. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
14. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
15. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
16. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA
Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476
[TBL] [Abstract][Full Text] [Related]
17. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
Xu L; Song X; Jia L
Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
[TBL] [Abstract][Full Text] [Related]
18. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
